share_log

A Glimpse Into The Expert Outlook On Janux Therapeutics Through 6 Analysts

Benzinga ·  Apr 16 08:00

In the latest quarter, 6 analysts provided ratings for Janux Therapeutics (NASDAQ:JANX), showcasing a mix of bullish and bearish perspectives.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings42000
Last 30D10000
1M Ago11000
2M Ago21000
3M Ago00000

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $63.83, along with a high estimate of $100.00 and a low estimate of $48.00. Marking an increase of 130.68%, the current average surpasses the previous average price target of $27.67.

price target chart

Analyzing Analyst Ratings: A Detailed Breakdown

A comprehensive examination of how financial experts perceive Janux Therapeutics is derived from...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment